Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Phase III Study to Assess Efficacy and Safety of STALORAL 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-Dust Mites
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors Stallergenes SA
- 14 Oct 2015 Results published in the Allergy
- 11 Oct 2011 Actual end date Jul 2009 added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed, according to a Stallergenes SA media release.